Summary
Boston Scientific Corporation (BSX) has filed an 8-K report detailing significant financing activities undertaken on April 21, 2020, as part of its COVID-19 response and mitigation plan. The company entered into a new $1.25 billion 364-day term loan, which was immediately used to refinance existing borrowings under its revolving credit facility, thereby increasing its available liquidity. This action, along with modifications to leverage covenants in its credit agreements, is intended to provide greater financial flexibility during the uncertain economic climate. Importantly, these transactions did not result in an increase in the company's total indebtedness.
Key Highlights
- 1BSX secured a new $1.25 billion 364-day term loan agreement on April 21, 2020.
- 2Funds from the new term loan were used to refinance existing borrowings under the revolving credit facility, enhancing liquidity.
- 3The company modified leverage covenants in its credit agreements to increase financial flexibility.
- 4The new term loan includes an accordion feature allowing for up to an additional $400.0 million in borrowings.
- 5The maximum leverage ratio was adjusted to 4.75x for fiscal quarters ending June 30, Sept 30, and Dec 31, 2020, and 4.5x for March 31, 2021.
- 6A deemed Consolidated EBITDA of $670.6 million was established for Q2, Q3, and Q4 of 2020 for covenant calculations.
- 7These financing activities did not increase Boston Scientific's total outstanding indebtedness.